Solid Biosciences to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Solid Biosciences (SLDB), focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences.
The company will present at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 2:15 pm ET, featuring President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks. A live webcast will be available on the company's website with a 90-day replay period.
Additionally, management will conduct one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 17, 2025. Institutional investors can arrange meetings through their Needham or Piper Sandler representatives.
Positive
- None.
Negative
- None.
News Market Reaction – SLDB
On the day this news was published, SLDB declined 5.62%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 24th Annual Needham Virtual Healthcare Conference
Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present on Thursday, April 10, 2025, at 2:15 pm ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page.
- Piper Sandler Spring Biopharma Symposium – Boston, MA
Management will participate in one-on-one meetings on Thursday, April 17, 2025.
Institutional investors interested in meeting with management during the conference may reach out to their Needham or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Solid Biosciences (SLDB) presenting at the Needham Healthcare Conference 2025?
How long will SLDB's Needham Conference webcast be available for replay?
Which executives from SLDB are presenting at the Needham Healthcare Conference?
When is Solid Biosciences participating in the Piper Sandler Spring Biopharma Symposium?
What type of medicines is Solid Biosciences (SLDB) developing?
